GenSight Biologics Reports Cash Position as of September 30, 2025

GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 3.7 Million

GenSight Biologics Reports Interim Financial Results for the First Half of 2025

GenSight Biologics Announces Successful Fundraising Amounting to Nearly EUR 3.7 Million

GenSight Biologics Postpones Release of 2025 Half-Year Financial Results

GenSight Biologics Announces the Closing of Approximately €500,000 of Additional Financing

GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy

GenSight Biologics Announces an Additional Financing Amounting to Approximately EUR 500,000 from Existing Shareholder

GenSight Biologics Reports Cash Position as of June 30, 2025

GenSight Biologics Announces the Closing of the Company’s c. €4 Million Private Placement